Developer docs
API playgroundTry for free, no card

Search company profiles

SkinVision

Full company profile

uuid0000p4r

Namestring
SkinVision
Legal namestring
SkinVision
Websiteurl
skinvision.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

SkinVision is a European health technology company founded in 2012 and headquartered in Amsterdam, Netherlands, that develops AI-powered mobile applications for skin cancer risk detection. The company operates a dual-product portfolio: a direct-to-consumer SkinVision App that allows individuals to photograph skin lesions and receive AI-generated risk indications, and SkinVision Pro, a B2B platform launched at HLTH Europe in 2026 that delivers AI-analyzed skin assessments directly to medical practices, providing doctors with structured patient information before consultations begin. The underlying technology is a computer vision pipeline trained on skin imagery, achieving clinically validated accuracy exceeding 90% sensitivity and 89% specificity for skin cancer detection, and holds CE marking as a Class IIa medical device in Europe.

SkinVision generates revenue through subscription-based models across both consumer and healthcare-provider segments. The consumer app targets individuals seeking accessible skin health monitoring and early detection, addressing pain points such as limited dermatology access and wait times of up to six months across health systems. SkinVision Pro targets healthcare providers, dermatology practices, and primary care networks as a triage solution, with early Dutch primary care data demonstrating 80% low-risk patient reassurance at home and 24% confirmed skin cancer diagnoses among high-risk patients. US market entry is pending FDA authorization, supported by a pivotal clinical trial partnership with Mayo Clinic announced in March 2026.

The company has raised approximately $16.5 million across eight funding rounds since inception, with strategic backing from Rubio Impact Ventures, LEO Pharma, and PHS Capital. SkinVision operates with 11-50 employees, a leadership team including CEO Erik de Heus and founder Victor Anastasiu, and is currently active in Europe while preparing for geographic expansion into the United States.

Short descriptiontext

SkinVision is a European health technology company that develops CE-marked AI-powered mobile applications for skin cancer risk detection, serving individual consumers through a subscription app and healthcare providers via its SkinVision Pro B2B platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAmsterdam, Netherlands
HQ citystring
Amsterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
skin cancer detection, AI dermatology app, teledermatology platform, medical imaging software, skin health monitoring
Industry3 codes
PRIMARYHLALAGAA
Dermatology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYCRABAAAJ
Skincare Devices & Beauty Tech (LED, Microcurrent, Cleansing Devices)
SECONDARYHSALADAN
Medical-Grade / Clinical Facials (Dermatology & Med Spa)
Product category
AI Dermatology Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Consumer App Subscriptions
TypeSubscription Recurring
Description

Mobile application offering skin health assessments to individual consumers, likely subscription-based model for ongoing monitoring and assessments.

skinvision.com
2Healthcare Provider Solutions (SkinVision Pro)
TypeSubscription Recurring
Description

B2B platform connecting AI skin assessments to medical practices and clinics, providing structured patient data before consultations.

aijourn.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 record
1SkinVision Pro
Description

AI-powered skin health platform that connects assessments directly to medical practices and clinics before consultations begin, providing doctors with structured patient information.

prnewswire.com
Core offering1 text field

SkinVision develops AI-powered skin health assessment technology delivered through a consumer-facing mobile application (SkinVision App) and a B2B platform (SkinVision Pro) that connects AI-analyzed skin assessments directly to medical practices. The technology uses computer vision algorithms on skin images to detect potential skin cancer with clinically validated accuracy of over 90% sensitivity and 89% specificity, and is CE-marked as a Class IIa medical device.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 90% sensitivity and 89% specificity for skin cancer detection
+2 more records
Product overview1 text field

SkinVision offers a dual-product portfolio consisting of the SkinVision App for consumer-facing skin health assessment and SkinVision Pro for healthcare provider integration. The SkinVision App enables individual users to conduct skin assessments and receive AI-powered risk indications, while SkinVision Pro connects these assessments directly to medical practices, giving doctors structured patient information before consultations begin. Both offerings are backed by the same clinically validated AI technology achieving over 90% sensitivity and 89% specificity for skin cancer detection.

Product and service2 records
1SkinVision App
CategoryConsumer Health App
Description

Health technology mobile application that enables individuals to assess skin conditions using smartphone-captured images, providing AI-powered risk indications to support early skin cancer detection and ongoing skin monitoring over time. Targeted at individual consumers in Europe.

2SkinVision Pro
CategoryClinical Decision Support Platform
Description

B2B platform that connects AI-powered skin health assessments directly to medical practices and clinics, providing doctors with structured patient information before consultations begin. Targeted at healthcare providers, dermatologists, and primary care practices across Europe.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

SkinVision has partnered with Mayo Clinic to conduct a pivotal clinical trial in the United States. The study aims to evaluate the app's performance and support FDA approval of its AI-based skin assessment app. This partnership represents a significant clinical validation opportunity and pathway to the US market, addressing rising skin cancer cases and systemic healthcare barriers.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Consumer-facing app for tracking moles and skin changes over time using smartphone photography. Comparable D2C GTM and skin-monitoring use case, though positioned for self-monitoring rather than regulatory-grade triage.

TypeDirect peer
Description

Developer of MoleScope (consumer dermatoscope attachment) and DermEngine (AI dermatology platform for clinicians). Comparable across both the consumer imaging and clinician AI-triage segments SkinVision serves.

TypeDirect peer
Description

UK-based AI dermatology platform offering similar clinical-grade skin cancer triage to GPs and dermatologists. Closest direct comparable: same technology category, same regulatory pathway (UKCA / CE), same provider-segment GTM.

TypeDirect peer
Description

European tele-dermatology service offering app-based image submission for dermatologist review within 24 hours. Comparable target customer (skin-aware consumer) and regulatory jurisdiction, with a human-in-the-loop rather than AI-first model.

TypeDirect peer
Description

US-based developer of an FDA-cleared AI-enabled point-of-care skin cancer evaluation device for primary care physicians. Comparable AI-triage product targeting the same dermatologist-shortage problem; provides a US regulatory benchmark for SkinVision's FDA pathway.

TypeBroad incumbent
Description

Large-scale telemedicine provider offering dermatology among many other virtual care specialties. Indirectly comparable as a tele-dermatology access channel for consumers and a platform partner / potential competitor for SkinVision Pro provider deployments.

TypeBroad incumbent
Description

Clinical decision support platform covering dermatology among other specialties, used by physicians for differential diagnosis. Comparable AI/visual-diagnostic technology stack, broader specialty footprint, and provider-segment sales motion.

8DermAssist (Google Health)
TypeBroad incumbent
Description

Google's AI dermatology assistant that lets consumers photograph skin conditions for triage. Comparable product and target user, but bundled within a broader consumer health portfolio and backed by Google's distribution and data resources.

TypeDirect peer
Description

Tele-dermatology platform connecting users to dermatologists for asynchronous image-based consultations. Adjacent GTM (skin image → remote clinician triage) and overlapping user base, but uses human clinicians rather than AI for triage.

TypeBroad incumbent
Description

Established German manufacturer of total body photography and AI-assisted dermoscopy systems used by dermatology clinics. Comparable clinical imaging and AI-triage category, but a hardware-centric incumbent rather than a smartphone-software-native play.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SkinVision

AI Dermatology Softwareskinvision.com

SkinVision is a European health technology company that develops CE-marked AI-powered mobile applications for skin cancer risk detection, serving individual consumers through a subscription app and healthcare providers via its SkinVision Pro B2B platform.

What SkinVision does

SkinVision is a European health technology company founded in 2012 and headquartered in Amsterdam, Netherlands, that develops AI-powered mobile applications for skin cancer risk detection. The company operates a dual-product portfolio: a direct-to-consumer SkinVision App that allows individuals to photograph skin lesions and receive AI-generated risk indications, and SkinVision Pro, a B2B platform launched at HLTH Europe in 2026 that delivers AI-analyzed skin assessments directly to medical practices, providing doctors with structured patient information before consultations begin. The underlying technology is a computer vision pipeline trained on skin imagery, achieving clinically validated accuracy exceeding 90% sensitivity and 89% specificity for skin cancer detection, and holds CE marking as a Class IIa medical device in Europe.

SkinVision generates revenue through subscription-based models across both consumer and healthcare-provider segments. The consumer app targets individuals seeking accessible skin health monitoring and early detection, addressing pain points such as limited dermatology access and wait times of up to six months across health systems. SkinVision Pro targets healthcare providers, dermatology practices, and primary care networks as a triage solution, with early Dutch primary care data demonstrating 80% low-risk patient reassurance at home and 24% confirmed skin cancer diagnoses among high-risk patients. US market entry is pending FDA authorization, supported by a pivotal clinical trial partnership with Mayo Clinic announced in March 2026.

The company has raised approximately $16.5 million across eight funding rounds since inception, with strategic backing from Rubio Impact Ventures, LEO Pharma, and PHS Capital. SkinVision operates with 11-50 employees, a leadership team including CEO Erik de Heus and founder Victor Anastasiu, and is currently active in Europe while preparing for geographic expansion into the United States.

SkinVision firmographics

Firmographics
Name
SkinVision
Legal name
SkinVision
Website
https://skinvision.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
SkinVision is a European health technology company that develops CE-marked AI-powered mobile applications for skin cancer risk detection, serving individual consumers through a subscription app and healthcare providers via its SkinVision Pro B2B platform.
Ownership category
akta.pro rank

SkinVision industry classification

Industry
Product category
AI Dermatology Software
akta.pro industry
PRIMARYHLALAGAA
Dermatology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYCRABAAAJ
Skincare Devices & Beauty Tech (LED, Microcurrent, Cleansing Devices)
SECONDARYHSALADAN
Medical-Grade / Clinical Facials (Dermatology & Med Spa)

Keywords

  • Skin cancer detection
  • AI dermatology app
  • Teledermatology platform
  • Medical imaging software
  • Skin health monitoring

Where SkinVision is headquartered

Location

Headquarters

HQ city
Amsterdam
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

SkinVision business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Consumer App Subscriptions: Mobile application offering skin health assessments to individual consumers, likely subscription-based model for ongoing monitoring and assessments.
  2. Healthcare Provider Solutions (SkinVision Pro): B2B platform connecting AI skin assessments to medical practices and clinics, providing structured patient data before consultations.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

SkinVision product offering

Product offering

Core offering

SkinVision develops AI-powered skin health assessment technology delivered through a consumer-facing mobile application (SkinVision App) and a B2B platform (SkinVision Pro) that connects AI-analyzed skin assessments directly to medical practices. The technology uses computer vision algorithms on skin images to detect potential skin cancer with clinically validated accuracy of over 90% sensitivity and 89% specificity, and is CE-marked as a Class IIa medical device.

Product overview

SkinVision offers a dual-product portfolio consisting of the SkinVision App for consumer-facing skin health assessment and SkinVision Pro for healthcare provider integration. The SkinVision App enables individual users to conduct skin assessments and receive AI-powered risk indications, while SkinVision Pro connects these assessments directly to medical practices, giving doctors structured patient information before consultations begin. Both offerings are backed by the same clinically validated AI technology achieving over 90% sensitivity and 89% specificity for skin cancer detection.

Differentiator

Problem solved

Functional benefit

Brands

  • SkinVision Pro: AI-powered skin health platform that connects assessments directly to medical practices and clinics before consultations begin, providing doctors with structured patient information.

Products and services

  • SkinVision App Health technology mobile application that enables individuals to assess skin conditions using smartphone-captured images, providing AI-powered risk indications to support early skin cancer detection and ongoing skin monitoring over time. Targeted at individual consumers in Europe.
  • SkinVision Pro B2B platform that connects AI-powered skin health assessments directly to medical practices and clinics, providing doctors with structured patient information before consultations begin. Targeted at healthcare providers, dermatologists, and primary care practices across Europe.

Quantifiable outcome

  • Over 90% sensitivity and 89% specificity for skin cancer detection
  • +2 more outcomes

Companies that use SkinVision

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

SkinVision technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

SkinVision partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Mayo CliniccoreStrategic or Co-development Partner · 1 March 2026SkinVision has partnered with Mayo Clinic to conduct a pivotal clinical trial in the United States. The study aims to evaluate the app's performance and support FDA approval of its AI-based skin assessment app. This partnership represents a significant clinical validation opportunity and pathway to the US market, addressing rising skin cancer cases and systemic healthcare barriers.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

SkinVision competitors and assessment

Company assessment

Direct peers

  • Miiskin: Consumer-facing app for tracking moles and skin changes over time using smartphone photography. Comparable D2C GTM and skin-monitoring use case, though positioned for self-monitoring rather than regulatory-grade triage.
  • MetaOptima (MoleScope / DermEngine): Developer of MoleScope (consumer dermatoscope attachment) and DermEngine (AI dermatology platform for clinicians). Comparable across both the consumer imaging and clinician AI-triage segments SkinVision serves.
  • Skin Analytics: UK-based AI dermatology platform offering similar clinical-grade skin cancer triage to GPs and dermatologists. Closest direct comparable: same technology category, same regulatory pathway (UKCA / CE), same provider-segment GTM.
  • iDoc24: European tele-dermatology service offering app-based image submission for dermatologist review within 24 hours. Comparable target customer (skin-aware consumer) and regulatory jurisdiction, with a human-in-the-loop rather than AI-first model.
  • DermaSensor: US-based developer of an FDA-cleared AI-enabled point-of-care skin cancer evaluation device for primary care physicians. Comparable AI-triage product targeting the same dermatologist-shortage problem; provides a US regulatory benchmark for SkinVision's FDA pathway.
  • First Derm: Tele-dermatology platform connecting users to dermatologists for asynchronous image-based consultations. Adjacent GTM (skin image → remote clinician triage) and overlapping user base, but uses human clinicians rather than AI for triage.

Broad incumbents

  • Teladoc Health: Large-scale telemedicine provider offering dermatology among many other virtual care specialties. Indirectly comparable as a tele-dermatology access channel for consumers and a platform partner / potential competitor for SkinVision Pro provider deployments.
  • VisualDx: Clinical decision support platform covering dermatology among other specialties, used by physicians for differential diagnosis. Comparable AI/visual-diagnostic technology stack, broader specialty footprint, and provider-segment sales motion.
  • DermAssist (Google Health): Google's AI dermatology assistant that lets consumers photograph skin conditions for triage. Comparable product and target user, but bundled within a broader consumer health portfolio and backed by Google's distribution and data resources.
  • FotoFinder Systems: Established German manufacturer of total body photography and AI-assisted dermoscopy systems used by dermatology clinics. Comparable clinical imaging and AI-triage category, but a hardware-centric incumbent rather than a smartphone-software-native play.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

SkinVision social profiles

Digital presence

SkinVision compliance and trust

Trust signal

Compliance1 record

SkinVision financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SkinVision leadership team

Management profile

Number of profiles

Profiles8 records

SkinVision funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SkinVision M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SkinVision

What does SkinVision do?

SkinVision develops AI-powered skin health assessment technology delivered through a consumer-facing mobile application (SkinVision App) and a B2B platform (SkinVision Pro) that connects AI-analyzed skin assessments directly to medical practices. The technology uses computer vision algorithms on skin images to detect potential skin cancer with clinically validated accuracy of over 90% sensitivity and 89% specificity, and is CE-marked as a Class IIa medical device.

Is SkinVision a public or private company?

SkinVision is a private company. It is classified as venture growth investor backed and is currently operating.

When was SkinVision founded?

SkinVision was founded in 2011. It employs 51 to 100 people.

Where is SkinVision based?

SkinVision is headquartered in Amsterdam, Netherlands, in the Europe region.

How does SkinVision make money?

Two revenue lines are on record. Consumer App Subscriptions are the primary driver. The others are healthcare Provider Solutions (SkinVision Pro).

Who are SkinVision's main competitors?

Direct peers on record are Miiskin, MetaOptima (MoleScope / DermEngine), Skin Analytics, iDoc24, DermaSensor and First Derm. Broad incumbents are Teladoc Health, VisualDx, DermAssist (Google Health) and FotoFinder Systems.

Does SkinVision have an API?

No public API is recorded for SkinVision.

What industry is SkinVision in?

SkinVision's product category is AI Dermatology Software. Its primary akta.pro industry code is HLALAGAA, Dermatology Telemedicine Platforms, with a secondary code of CRABAAAJ, Skincare Devices & Beauty Tech (LED, Microcurrent, Cleansing Devices).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournSkinVision Pro Launches Globally at HLTH Europe: AI-powered Skin Health Platform Connected To Healthcare ProvidersSkinVision launched SkinVision Pro at HLTH Europe, a platform connecting AI-powered skin health assessments directly to medical practices, giving doctors structured patient information before consultations begin. The SkinVision Service is CE-marked as a Class IIa medical device with clinically validated accuracy of over 90% sensitivity and 89% specificity for skin cancer detection, with early real-world data from Dutch primary care showing 24% of high-risk indication patients received a confirmed diagnosis. The launch responds to tripling skin cancer incidence over two decades and dermatology wait times reaching up to six months in many health systems.PR NewswireSkinVision Pro Launches Globally at HLTH Europe: AI-powered Skin Health Platform Connected To Healthcare ProvidersSkinVision launched SkinVision Pro at HLTH Europe in Amsterdam on June 16, 2026, a platform that connects AI-powered skin health assessments directly to medical practices and clinics before consultations begin. The CE-marked Class IIa medical device achieves over 90% sensitivity and 89% specificity for skin cancer detection, with early Q1 2026 Dutch primary care data showing 80% of low-risk patients were reassured at home and 24% of high-risk patients received confirmed skin cancer diagnoses. The launch addresses skin cancer incidence that has tripled over two decades and dermatology wait times reaching up to six months across health systems.PR NewswireSkinVision Collaborates on Pivotal Trial to Improve Access to Dermatology Care in the United StatesSkinVision and Mayo Clinic have entered a research collaboration to conduct a pivotal trial required by the U.S. FDA to support SkinVision's regulatory pathway for its AI-powered skin health assessment app in the United States. The study will evaluate the app's performance for assessing skin spots while exploring how digital tools can improve access to dermatology guidance amid national workforce shortages and geographic disparities. Mayo Clinic has a financial interest in the referenced technology.The Independent“I was afraid of being overcautious, and that almost cost me my life” – Jacqui’s Journey With MelanomaA 54-year-old woman from the UK discovered a changing spot on her leg and, after using the SkinVision skin cancer detection app, was prompted to seek medical attention that led to a malignant melanoma diagnosis.EIN PresswireArtificial Intelligence (AI)-Powered Dermatology Lesion Triaging Market Projected to Reach $3.39 Bn 31.9% CAGR by 2029The Business Research Company published a market report projecting the AI-powered dermatology lesion triaging market to grow from $0.85 billion in 2024 to $3.40 billion by 2029, representing a compound annual growth rate of 31.9%. Key growth drivers include the increasing incidence of skin cancer, rising demand for personalized medicine, and greater adoption of digital health solutions in healthcare settings. Major players identified in the market include Proscia Inc., SkinVision B.V., MetaOptima Technology Inc., DermaSensor Inc., and Enspecta Health Inc., which recently received FDA breakthrough device designation for its AI-based VIO Skin platform.WebelightBuild Multimodal AI Apps: Voice & Visual Search APIs USAThis article provides an educational overview of multimodal AI technology, explaining how combining voice and visual search APIs enables applications that process multiple input types simultaneously for improved accuracy and user experience. It documents implementation case studies across retail (Pinterest, Amazon, Sephora, Walmart, IKEA), FinTech (Bank of America, Capital One), healthcare (SkinVision, Buoy Health), and logistics (Amazon, DHL, UPS), detailing how each company deploys image and voice-based AI features. The piece also covers technical architecture principles, development tools and APIs, compliance considerations, and emerging trends including Google's Gemini and Meta's Llama 3.2 models.The Medical FuturistDigital Skin Care: Top 8 Dermatology AppsThis article provides an overview of the top dermatology apps available for smartphone users, highlighting how the proliferation of smartphones (now owned by approximately 75-90% of the population in most countries) has enabled the growth of digital dermatology solutions offering self-check and teleconsultation services. Key apps discussed include SkinVision (Amsterdam-based, used by nearly 2 million users who detected over 55,000 skin cancer cases), iDoc24/FirstDerm (which found 70% of reviewed cases could be self-treated), Cureskin (India-based AI app developed by former Google engineers), and VisualDx (used by thousands of hospitals and medical schools for clinical decision support). The article positions these apps as cost-effective alternatives to traditional dermatology appointments, particularly valuable given global dermatologist shortages such as India having fewer than one dermatologist per 100,000 people.HalecosmeceuticalsPersonalized Skincare Trends: Future Innovations in Professional SettingsThe skincare industry is evolving through the adoption of AI-powered analysis and DNA-driven formulations to provide highly personalized treatments for consumers. Key companies such as Proven Skincare, SkinVision, and Genetic Skincare are leveraging these technologies to tailor regimens based on individual data and genetic markers. This shift also involves custom compounding techniques and workflow automation tools like SpaSoft to enhance operational efficiency and client care.Startups MagazineAI in healthcare: why regulation is the key to trustThe article argues that strict regulatory frameworks, such as the EU's Medical Device Regulation (MDR), are essential for ensuring safety and building trust in AI healthcare technologies. It highlights SkinVision's successful acquisition of MDR Class IIa certification as a case study demonstrating how rigorous compliance leads to commercial success through increased credibility and global partnerships.